Safety of SGLT2 inhibitors, DPP-4 inhibitors, and GLP-1 receptor agonists in US veterans with and without chronic kidney disease: a population-based study

By sjmartinez • July 13, 2024

Narasaki Y, Kovesdy CP, You AS, Sumida K, Mallisetty Y, Surbhi S, Thomas F, Amin AN, Streja E, Kalantar-Zadeh K, Rhee CM. Safety of SGLT2 inhibitors, DPP-4 inhibitors, and GLP-1 receptor agonists in US veterans with and without chronic kidney disease: a population-based study. Lancet Reg Health Am. 2024 Jun 18;36:100814. doi: 10.1016/j.lana.2024.100814. PMID: 38993538; PMCID: PMC11237921.

Tags: Harbor UCLA, Nephrology, Publications, Veterans Administration

Redifferentiation therapy in unresectable or metastatic radioactive iodine refractory thyroid cancer: an International Thyroid Oncology Group statement

Leboulleux S, Boucai L, Busaidy N, Durante C, Fagin JA, Fazeli S, Gianoukakis AG, Haugen BR, Kang H, Konda B, Laetsch TW, Locati L, Ryder[...]

Heterozygous NTHL1 variant in a breast cancer survivor with malignant pleural effusion revealing metastatic colon adenocarcinoma

Lewis LK, Varda MM, McCann KE, Huang C. Heterozygous NTHL1 variant in a breast cancer survivor with malignant pleural effusion revealing metastatic colon adenocarcinoma. BMJ[...]

CTA-Derived Plaque Characteristics and Risk of Acute Coronary Syndrome in Patients With Coronary Artery Calcium Score of Zero: Insights From the ICONIC Trial

Jonas RA, Nurmohamed NS, Crabtree TR, Aquino M, Jennings R, Choi AD, Lin FY, Lee SE, Andreini D, Bax J, Cademartiri F, Chinnaiyan K, Chow[...]